Check out Exelixis website of the actively recruiting and also to be recruiting trials is all sorts of cancers for cabo by the National Cancer Institute. These are different than those trials by Exelixis itself. The National Cancer Institute would not be wasting their time on these trials if they did not believe in Cabo and the science.
Here is purpose and appears there will be a lot of triggers upward in the stock price.
"In November 2011, we entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute’s Cancer Therapy Evaluation Program (NCI-CTEP). The CRADA provides for as many as 20 active clinical trials each year for a five-year period, and the agreement reflects a commitment by NCI-CTEP to support the exploration of cabozantinib's potential in a wide variety of cancers. We believe that this agreement will allow us to broadly expand the cabozantinib development program and substantially increase the number of indications and disease settings in which cabozantinib is being investigated."
Cabo certainly has blockbuster potential to be used to treat multiple cancer types.